News

Catalent Cell and Gene Therapy
Catalent Cell and Gene Therapy is a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent’s experience in autologous and allogeneic cell therapy complements its industry-leading expertise and commercial success in gene therapy development, manufacturing, and adeno-associated virus (AAV) vector production. Its cell therapy offering includes expertise with a variety of cell types including chimeric antigen receptor T cells (CAR-T). With facilities in the US and Europe and continued new investments, Catalent is dedicated to supporting its customers and their patients. Catalent has produced more than 100 cGMP batches across 60+ clinical and commercial programs.
Nasdaq
by Nick Paul Taylor Adicet Bio has struck a deal to merge with resTORbio, bagging itself a Nasdaq listing to support its pipeline of allogeneic gamma delta CAR-Ts.

by Amirah Al Idrus With 15 programs, $30 million, and a partnership with UT Southwestern, Taysha Gene Therapies plans to be in the clinic by the end of the year.
Lungs
by Arlene Weintraub Two NSCLC patients who received Iovance's personalized cell therapy in an early trial achieved complete responses that have lasted more than a year.
Sanofi
by Ben Adams Sanofi is culling a Regeneron-partnered med and still looking for partners for two unwanted pipeline candidates.

by Angus Liu Scientists reversed diabetes in mice by using CRISPR to correct a faulty gene in human-induced pluripotent stem cells and turn them into beta cells.
Gilead
by Ben Adams All the attention is currently laser-focused on Gilead’s COVID-19 hopeful remdesivir, but the company itself is still penning deals in cancer.
Sangamo CEO Sandy Macrae
by Nick Paul Taylor Sangamo is paying an upfront fee to get Mogrify to apply its direct cell conversion technology to the generation of regulatory T cells.  
Bellicum researcher
by Nick Paul Taylor Bellicum doesn’t expect MD Anderson’s actions to “have a significant impact” on its programs but warned they may prevent study enrollment.

by Amirah Al Idrus In a deal with $30 million upfront, Novartis and TScan are on the hunt for targets that could lead to new T-cell receptor therapies for solid cancers.
Blue purple pink 3d rendering of brain
by Arlene Weintraub Swedish scientists turned skin cell into nerve cells, which helped repair stroke-damaged nerve circuits when implanted in the brains of rat models.


Excerpt from URL:https://www.fiercebiotech.com/topic/cell-gene-therapy



  ▲ Last article:   Consumer Health ---20201015
  ▼ Next article:   Sherlock, Mologic to develop 'instrument-free' molecular tests ---Oct 30, 2019
                    More ……      

 



News FullText Search